A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...

Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

Read the latest. Irish national Stephen Frances Roche, 46, was expected to front Darwin Local Court on Tuesday, charged with a single count of providing support for the offence of people smuggling.

Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with diabetes. Susvimo, also ...